ANXA1 (Ab-21) Antibody

What is ANXA1 and what are its main biological functions?

Annexin A1 (ANXA1) is a calcium/phospholipid-binding protein that plays multiple critical roles in cellular physiology. It functions prominently in the innate immune response as an effector of glucocorticoid-mediated responses and regulator of inflammatory processes . ANXA1 displays significant anti-inflammatory activity and mediates glucocorticoid-induced down-regulation during early inflammation . In the adaptive immune system, ANXA1 enhances signaling cascades triggered by T-cell activation, regulates T-cell differentiation (promoting Th1 over Th2 differentiation), and affects T-cell proliferation . Additionally, ANXA1 regulates hormone exocytosis through formyl peptide receptor activation and actin cytoskeleton reorganization . It exhibits high calcium-binding affinity (up to eight Ca²⁺ ions) and participates in phagocytosis by mediating calcium-dependent interactions between phagosomes and the actin cytoskeleton .

What is the ANXA1 (Ab-21) antibody specifically targeting?

The ANXA1 (Ab-21) antibody is designed to recognize and bind to human ANXA1 protein specifically around the phosphorylation site of tyrosine 21 (Q-E-YP-V-Q) . This specificity for the phosphorylated form makes it particularly valuable for studying post-translational modifications of ANXA1. The antibody is typically generated by immunizing rabbits with a synthetic peptide derived from this region of human ANXA1 . This targeted approach allows researchers to investigate specifically how phosphorylation at this site affects ANXA1 function in various cellular processes.

What applications is the ANXA1 (Ab-21) antibody validated for?

The ANXA1 (Ab-21) antibody has been validated for multiple research applications:

• Western Blotting (recommended dilutions ranging from 1:500 to 1:3000)

• ELISA (recommended dilution of 1:20000)

• Some formulations may be suitable for immunofluorescence and flow cytometry

Testing has confirmed reactivity with human samples, with some antibody formulations also cross-reacting with mouse, rat, and monkey samples depending on the specific clone . Validation typically involves testing against cell lines known to express ANXA1, such as A549 and MDA-MB-231, with appropriate controls including ANXA1 knockout cell lines .

What are the optimal storage conditions for maintaining ANXA1 (Ab-21) antibody activity?

For optimal preservation of ANXA1 (Ab-21) antibody activity, storage conditions should be carefully maintained. The antibody should be stored at -20°C for long-term storage, with some manufacturers recommending -80°C for extended periods . For short-term storage (up to two weeks), 2-8°C is generally acceptable . The antibody is typically supplied in a buffer containing PBS (pH 7.4) without Mg²⁺ and Ca²⁺, with 0.02% sodium azide and 50% glycerol to prevent freeze-thaw damage . To minimize activity loss, it is critical to aliquot the antibody upon receipt rather than repeatedly freeze-thawing the original vial . Most manufacturers indicate a shelf-life of approximately 12 months from the shipping date when stored properly .

How should I optimize Western blot protocols when using ANXA1 (Ab-21) antibody?

For optimal Western blot results with ANXA1 (Ab-21) antibody:

• Sample preparation:

  • Use 25-35 μg of total protein per lane for cell lysates

  • Include phosphatase inhibitors if detecting phosphorylated forms

• Dilution optimization:

  • Start with 1:1000 dilution in 5% BSA or non-fat milk in TBST

  • Adjust concentration based on signal intensity (range: 1:500-1:3000)

• Secondary antibody selection:

  • Use anti-rabbit IgG conjugated to HRP at 1:5000 dilution

  • Consider signal amplification systems for low abundance samples

• Detection parameters:

  • ANXA1 appears at approximately 37 kDa on SDS-PAGE

  • Include positive controls (A549 or MDA-MB-231 cell lysates)

  • Include negative controls when possible (ANXA1 knockout samples)

• Troubleshooting:

  • For high background: increase blocking time, reduce antibody concentration

  • For weak signal: reduce washing stringency, increase antibody concentration or incubation time

What controls should be included when validating ANXA1 (Ab-21) antibody specificity?

Proper control selection is critical for validating ANXA1 (Ab-21) antibody specificity:

The multi-tissue microarray (TMA) validation approach is particularly valuable for comprehensive specificity testing across different tissue contexts . Western blot analysis should reveal a single predominant band at approximately 37 kDa, while any additional bands warrant investigation as potential non-specific interactions or ANXA1 isoforms .

How does ANXA1 expression correlate with cancer progression and patient outcomes?

ANXA1 expression has complex and often tissue-specific associations with cancer progression and patient outcomes:

What mechanisms underlie ANXA1's influence on tumor microenvironment?

ANXA1 modulates the tumor microenvironment through multiple mechanisms:

• Immune cell regulation:

  • Enhances regulatory T-cell function and suppression capacity

  • Promotes polarization and activation of M2 tumor-associated macrophages

  • Suppresses dendritic cell activation

  • Impairs CD8+ T-cell anti-tumor immunity

• Extracellular vesicle components:

  • ANXA1 is a key component of tumor-derived extracellular vesicles

  • Promotes migration, invasion and angiogenesis through vesicle-mediated signaling

• Cancer-associated fibroblast interactions:

  • Secreted by cancer-associated fibroblasts to increase cancer stem cell generation

  • Mediates communication between stromal and malignant cells

• Signaling pathway activation:

  • Functions through activation of formyl peptide receptors (FPR1/FPR2)

  • Initiates complex intracellular signaling networks affecting multiple cellular responses

  • Influences inflammatory mediator production in the tumor microenvironment

These mechanisms collectively create an immunosuppressive microenvironment that facilitates tumor progression while evading immune surveillance, making ANXA1 a potential therapeutic target for cancer immunotherapy approaches .

What is the current evidence for targeting ANXA1 in cancer therapy?

Recent investigations provide promising evidence for ANXA1-targeted cancer therapy:

A groundbreaking study evaluated MDX-124, a humanized IgG1 monoclonal antibody specifically designed to target ANXA1, disrupting its interaction with formyl peptide receptors (FPR1/2) . This novel therapeutic approach demonstrated significant anti-cancer effects across multiple experimental systems:

• In vitro effects: MDX-124 significantly reduced proliferation (p < 0.05) in a dose-dependent manner across multiple human cancer cell lines expressing ANXA1 . The mechanism involved cell cycle arrest with cancer cells accumulating in the G1 phase .

• In vivo efficacy: MDX-124 significantly inhibited tumor growth (p < 0.0001) in both 4T1-luc triple-negative breast cancer and Pan02 pancreatic cancer syngeneic mouse models .

• Specificity: The anti-proliferative effects were specifically associated with ANXA1 expression, as non-expressing cell lines showed no response to MDX-124 treatment .

Additionally, research using the ANXA1 blocker Boc1 demonstrated reduced tumor size and downregulated Treg cell function in animal models, providing further support for ANXA1 as a therapeutic target . These findings collectively suggest that ANXA1-targeted therapy represents a viable and innovative approach for treating tumors that overexpress ANXA1, particularly in cancer types with poor prognosis and limited treatment options .

How does ANXA1 mediate glucocorticoid anti-inflammatory effects?

ANXA1 serves as a critical mediator of glucocorticoid anti-inflammatory effects through multiple interrelated mechanisms:

These mechanisms collectively explain why ANXA1 has been characterized as a crucial effector of glucocorticoid-mediated responses and a key regulator of the inflammatory process, particularly in resolving inflammation rather than simply suppressing it .

What is the significance of anti-ANXA1 antibodies in autoimmune conditions?

Anti-ANXA1 antibodies have emerged as significant biomarkers and potential pathogenic factors in autoimmune conditions:

Studies have revealed that anti-ANXA1 antibodies are present at significantly higher levels in sera of patients with cutaneous lupus erythematosus (CLE) compared to normal healthy donors . This finding is particularly pronounced in the discoid lupus erythematosus (DLE) subtype, where the percentage of sera testing positive for anti-ANXA1 antibodies is significantly elevated .

The pathophysiological significance of these antibodies likely relates to ANXA1's normal anti-inflammatory functions. Anti-ANXA1 antibodies could potentially neutralize this protein's activities, disrupting normal inflammatory resolution processes and contributing to the persistent inflammation characteristic of autoimmune conditions. This mechanism may be particularly relevant in conditions with prominent skin manifestations, given ANXA1's role in cutaneous inflammation regulation.

How does ANXA1 influence adaptive immunity and T-cell function?

ANXA1 exerts complex regulatory effects on adaptive immunity and T-cell function:

A critical aspect of ANXA1's influence on T-cell function is its role in directing T-cell differentiation pathways. Research has demonstrated that ANXA1 promotes the differentiation of T-cells into Th1 cells while negatively regulating differentiation into Th2 cells . This polarizing effect on T-helper cell subsets has significant implications for both infectious and autoimmune disease contexts.

Additionally, ANXA1 significantly impacts regulatory T (Treg) cell function. Studies show that ANXA1 can enhance the suppressive function of Treg cells, which has important implications for cancer immunology . Targeting ANXA1 with blockers like Boc1 can reduce Treg cell function in experimental models, suggesting a potential therapeutic approach for enhancing anti-tumor immunity .

The mechanisms underlying these effects involve ANXA1 activation of formyl peptide receptors (particularly FPR1 and FPR2), which initiates complex signaling cascades affecting T-cell development, activation, and effector functions . RNA sequencing analysis revealed that blocking ANXA1 can reduce the expression of granzyme A mRNA in Treg cells, providing insight into the molecular mechanisms of ANXA1's immunomodulatory effects .

How do post-translational modifications affect ANXA1 function and antibody recognition?

Post-translational modifications (PTMs) critically influence both ANXA1 function and antibody recognition:

Key ANXA1 Modifications and Their Functional Impact:

• Phosphorylation:

  • Tyrosine 21 phosphorylation (target of Ab-21 antibody) affects membrane binding and subcellular localization

  • Serine 27 phosphorylation by PKC regulates secretion and extracellular functions

  • Multiple phosphorylation events can occur during cell activation, changing protein conformation

• Proteolytic Cleavage:

  • N-terminal cleavage generates bioactive peptides with distinct receptor binding properties

  • Affects stability and functional activity of the protein

• SUMOylation and Ubiquitination:

  • Influence protein turnover and nuclear localization

  • May affect interactions with binding partners

Implications for Antibody Recognition:
The specificity of ANXA1 (Ab-21) antibody for the phosphorylated tyrosine 21 region means that detection is highly dependent on the phosphorylation state of the protein . Research suggests that the role of ANXA1 may be tissue-specific due to these post-translational modifications impacting expression across different cell types or cancer indications . When interpreting experimental results, researchers must consider whether antibody recognition might be masked or enhanced by specific PTMs present in their experimental system. This can lead to apparent discrepancies in protein detection between different tissues or experimental conditions, even when ANXA1 is present.

What approaches can resolve contradictory findings regarding ANXA1's role in different cancers?

Addressing contradictory findings regarding ANXA1's role in cancer requires multi-faceted research approaches:

• Context-specific analysis:

  • Implement tissue-specific and cancer subtype-specific investigations

  • Analyze ANXA1 expression in relation to cancer stage and molecular classification

  • Consider microenvironmental factors that may influence ANXA1 function

• Post-translational modification profiling:

  • Characterize ANXA1 PTM patterns in different cancer types

  • Correlate specific modifications with functional outcomes

  • Utilize phospho-specific antibodies like Ab-21 to distinguish modified forms

• Mechanistic investigations:

  • Examine ANXA1 interaction partners in various cancer contexts

  • Identify downstream signaling pathways activated in different tumors

  • Consider receptor expression (FPR1/FPR2) in the cellular context

• Comprehensive experimental models:

  • Combine in vitro, in vivo, and clinical sample analyses

  • Develop conditional knockout models for tissue-specific ANXA1 deletion

  • Use patient-derived xenografts to maintain tumor heterogeneity

• Integrated multi-omics approaches:

  • Correlate transcriptomic, proteomic, and phospho-proteomic data

  • Apply network analysis to identify context-dependent regulatory mechanisms

  • Consider epigenetic regulation of ANXA1 expression

Research suggests that ANXA1's contradictory roles may be explained by its tissue-specific post-translational modifications affecting expression and function across different cancer indications . This underscores the importance of comprehensive analysis before generalizing findings from one cancer type to another.

What are the key considerations for developing next-generation anti-ANXA1 therapeutic antibodies?

Developing next-generation anti-ANXA1 therapeutic antibodies requires addressing several critical considerations:

• Epitope selection and specificity:

  • Target functionally critical domains (N-terminal region vs. core domain)

  • Consider phosphorylation-specific antibodies (like Ab-21 concept) to target specific functional states

  • Evaluate cross-reactivity with other annexin family members

• Antibody format optimization:

  • Compare full IgG vs. alternative formats (Fab, scFv, nanobodies)

  • Evaluate antibody-drug conjugates for enhanced cancer cell targeting

  • Consider bispecific antibodies targeting ANXA1 and immune checkpoint molecules

• Mechanism of action characterization:

  • Determine whether blocking FPR1/2 interactions is sufficient for therapeutic effect

  • Assess antibody-dependent cellular cytotoxicity potential

  • Evaluate impact on ANXA1 internalization and degradation

• Predictive biomarkers development:

  • Establish ANXA1 expression thresholds for treatment response

  • Identify companion diagnostics to select appropriate patients

  • Consider post-translational modification patterns as response predictors

• Combination therapy strategies:

  • Evaluate synergy with immune checkpoint inhibitors

  • Assess compatibility with conventional chemotherapy

  • Consider combination with radiotherapy based on ANXA1's roles in damage response

Research with MDX-124, a humanized IgG1 monoclonal antibody targeting ANXA1, has demonstrated promising anti-cancer effects by disrupting ANXA1 interaction with formyl peptide receptors . Similarly, studies with the ANXA1 blocker Boc1 have shown efficacy in reducing tumor size and modulating Treg function . These proof-of-concept studies provide valuable insights for developing increasingly refined therapeutic approaches targeting ANXA1 in cancer and potentially autoimmune conditions.

What factors affect ANXA1 (Ab-21) antibody sensitivity in Western blotting applications?

Multiple factors can significantly impact ANXA1 (Ab-21) antibody sensitivity in Western blotting:

Different cell lines show variable ANXA1 expression levels, with A549 and MDA-MB-231 serving as reliable positive controls . The phosphorylation state of tyrosine 21 may change during experimental manipulations, affecting antibody binding and detection sensitivity . Researchers should optimize protocols specifically for their sample types and experimental conditions.

How can I validate ANXA1 (Ab-21) antibody specificity for mechanistic studies?

Comprehensive validation of ANXA1 (Ab-21) antibody is essential for mechanistic studies:

• Genetic validation approaches:

  • CRISPR/Cas9-mediated ANXA1 knockout serves as definitive negative control

  • Site-directed mutagenesis of Tyr21 to non-phosphorylatable residue (Y21F)

  • Overexpression systems with wild-type vs. Y21F mutant ANXA1

• Biochemical validation methods:

  • Peptide competition assays using the immunizing peptide (Q-E-YP-V-Q)

  • Lambda phosphatase treatment to remove phosphorylation

  • Immunoprecipitation followed by mass spectrometry confirmation

• Advanced specificity assessments:

  • Multi-tissue microarray analysis across different tissues and conditions

  • Parallel testing with multiple anti-ANXA1 antibodies targeting different epitopes

  • Cross-species reactivity testing if performing comparative biology

• Functional validation approaches:

  • Correlate antibody detection with known ANXA1 functions

  • Verify binding patterns during cellular processes known to modify ANXA1

  • Assess detection during stimulus-induced phosphorylation events

For phospho-specific antibodies like Ab-21, validation should particularly focus on demonstrating phosphorylation-dependent recognition. Researchers should document robust evidence of specificity before proceeding to mechanistic studies where accurate detection of phospho-ANXA1 is critical for interpretation.

What experimental design considerations are essential when studying ANXA1 in complex biological systems?

Studying ANXA1 in complex biological systems requires careful experimental design:

• Context-appropriate models:

  • Consider basal ANXA1 expression levels in chosen model systems

  • For cancer studies, select models reflecting appropriate ANXA1 expression patterns

  • For immunological studies, consider differences between mouse and human ANXA1 biology

• Temporal considerations:

  • ANXA1 functions change dynamically during inflammatory responses

  • Design time-course experiments to capture acute vs. resolution phases

  • Account for circadian regulation of glucocorticoids and ANXA1 expression

• Spatial localization analysis:

  • ANXA1 functions differently in different subcellular compartments

  • Extracellular vs. intracellular ANXA1 may have distinct roles

  • Implement fractionation approaches to distinguish compartment-specific functions

• Analytical considerations:

  • Use multiple detection methods (Western blot, IHC, flow cytometry)

  • Implement quantitative approaches (ELISA, quantitative imaging)

  • Consider single-cell analyses to address cellular heterogeneity

• Pathway interference strategies:

  • Compare genetic manipulation (CRISPR, siRNA) with antibody neutralization

  • Consider specific inhibition of ANXA1-receptor interactions using Boc1

  • Use receptor knockouts/antagonists to distinguish receptor-dependent functions

• Translational relevance:

  • Include clinically relevant samples when possible

  • Consider both mouse and human systems to address species differences

  • Design experiments with potential diagnostic or therapeutic applications in mind